Navigation Links
Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
Date:10/14/2008

as every 15-30 minutes in more severe cases. In addition, Durezol does not contain benzalkonium chloride (BAK), a common ocular preservative known to cause corneal toxicity with long-term use. This is especially important for patients with uveitis, which is a chronic disease. A strong steroid like Durezol will be a very valuable tool for ophthalmologists everywhere, allow patients to have an easier dosing regimen, and will most likely become the new standard of care for treating uveitis."

In addition to reducing mean cell grade, a greater percentage of patients receiving Durezol had an AC cell grade of 0 (less than or equal to 1 cell) than did the Pred Forte group at Day 14 (69% vs 62%, respectively). This trend continued through Day 42.

Ocular discomfort and pain is a debilitating symptom of uveitis. In this study, pain was assessed using a Visual Analog Scale. Durezol demonstrated a numerical advantage in pain reduction from baseline over Pred Forte at every time point in the study. As early as Day 3, the Durezol group had a reduction in mean pain score of 58% vs 51% in the Pred Forte group. At Day 7, these were 71% and 64%, respectively.

Durezol was also very effective in reducing the symptoms of anterior ocular inflammation (pain/ocular discomfort, photophobia, blurred vision, and lacrimation). The Durezol group achieved a mean reduction in total symptom score of 76% vs 71% for Pred Forte at Day 14. This numerical difference was maintained through Day 42 with the Durezol group reducing the total symptom score by 86% vs 76% for the Pred Forte group.

The total sign score was also reduced to a greater degree in the Durezol group when compared to the Pred Forte group: 6.5 vs 6.1 at Day 14, respectively. Total sign score included the sums of posterior synechiae, hypopyon, limbal injection, peripheral anterior synechiae, AC flare, AC cell and keratic precipitate grades. The numerical advantage of Durezol over Pred Forte in total sign score
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
2. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...ICK, Md., Jan. 7 ImQuest Life Scie...an IND application to the Food and Drug Administra...ead pyrimidinedione HIV inhibitor IQP-0410. ImQues...the first quarter of 2009. IQP-0410 is a novel sma...as a nonnucleoside reverse transcriptase inhibitor...
(Date:1/6/2009)...m Expands on Successful Results from prior U.S., U...ewswire/ -- Vital Therapies, Inc. (VTI), a develop...announced patient enrollment has begun for a rando...trial that will study the Extracorporeal Liver Ass... Acute Liver Failure (ALF) under three protocols. ...
(Date:1/6/2009)...LLE, Md., Jan. 6 Sequel...ny focused on diseases of epidemic potential, anno...r the treatment of tuberculosis (TB), was the firs...clinical program contract to Dynport Vaccine Compa...awarded by the National Institute of Allergy and I...
(Date:1/5/2009)...EGO, Jan. 5 Cylene Pharmaceuticals...linical trial of its oral CK2 protein kinase inhib...ors, Castleman,s disease, or multiple myeloma. The...al are determination of safety, tolerance and PK p... dose for Phase II trials. In addition, multiple m...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3The sea ice is getting thinner 372 1The sea ice is getting thinner 372 2The sea ice is getting thinner 372 3The sea ice is getting thinner 372 4Nucletron Announces Management Buy Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community 1185 1Nucletron Announces Management Buy Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community 1185 2Nucletron Announces Management Buy Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community 1185 3MDMA Names New Director of Federal Affairs 1180 1MDMA Names New Director of Federal Affairs 1180 2Metabolic syndrome heightens risk for development of uric acid kidney stones 1179 1Metabolic syndrome heightens risk for development of uric acid kidney stones 1179 2
...agonist shown to be therapeutically effective in a...PENHAGEN, 18 April 2007 - Santaris Pharma, the Dan...s, yesterday,presented encouraging data at the Ame...ng in Los Angeles, showing that SPC2996, the,Compa...ctive in a,preclinical model of human Chronic Lymp...
...Calif., April 18, 2007 /PRNewswire-FirstCall/ -- K...linical data on its,proprietary nuclear export inh...ting and long-lasting anticancer activity with a,h... xenograft,cancer models. , Kosan,s NEIs are poten..., essential protein that exports key regulatory pr...
Other Medicine Technology:Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 2Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 3Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 4Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 5Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research 6Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR 4
(Date:1/8/2009)...e Promoted to Principal. Christine Siu and Jason ...NEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan. ... a health care venture capital firm that invests i...oday announced the promotion of three members of i...to Principal. Christine Siu and Jason Brown have ...
(Date:1/8/2009)...tically-navigated guidewire provides minimally-inv..., AUSTIN, Texas, Jan. 8 The Hear... world to use the new Stereotaxis RF PowerAssert(T...c total occlusions (CTOs), or complete blockages i...Austin Heart interventional cardiologist, Frank Zi...
(Date:1/8/2009)...n University and Baxter Healthcare Corporation wil...on alliance, the two entities announced today. , ...will fund research-collaboration projects at North...proximately $1 million, and Baxter will determine ...basis. Aligned with Baxter,s diversified business ...
(Date:1/8/2009)...a., Jan. 8 The National eHealth Co...announced the results of its organizational leader...t and CEO of Prematics, Inc., was elected to serve... Directors. The Collaborative builds on the accom...unity (AHIC), a federal advisory committee establi...
Breaking Medicine News(10 mins):Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2Health News:Heart Hospital of Austin First in World to Use New Device for Blocked Arteries 2Health News:Baxter and Northwestern University partner to target new life sciences projects 2Health News:Kevin Hutchinson Elected Vice Chair of Board of Directors for National eHealth Collaborative 2
...he Washington University School of Medicine in St....ck the butt by revealing that smoking interferes ... study on a mouse model and found that cigarette s...ls to the injury site and delays healing following...
... ramp for nearly 20 years, it seems that time is t...ed at Sir Paul McCartney's 65th birthday party in ...legs. The dress, a cream Old Hollywood-style garme...' favorite, since it was worn by her on her own bi...
...s well as tourists are heading for the nearest bee... a chilled glass of beer . This is evident from t...e packed with guzzlers. Over ninety percent of the...eer with a mere ten percent opting for hard liquor...
...dy found that younger menopausal women (aged 50-59...estrogens had significantly less coronary artery c...red with those taking placebo. Coronary artery cal...e arteries and a predictor of future cardiovascula...
Other Medicine News:Health News:Smoking Hampers Healing of the Ligament 2Health News:Women Taking Oestrogen Therapy Showed Reduced Coronary Artery Calcification 2
John weiss, wright acrylic globe.
Guthrie fixation hook, sharp double prongs.
Joseph Double Hook 10 mm wide. Designated most popular model or size.
Freer skin hook with blunt double prongs.
Medicine Products: